US equities |
NVDA $238.84 ▲+2.09% SPCX $170.82 ▲+7.46% MU $1,062.33 ▼-1.17% TSLA $378.48 ▲+2.13% SNDK $1,702.33 ▼-1.03% MSFT $524.18 ▲+1.28% INTC $115.97 ▼-2.82% META $741.52 ▲+1.85%
FinancialContent

Articles published by Werewolf Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Pipeline and Business Updates
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in the BIO International Convention
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
< Previous 1 2 Next >